GO
| HSI1 | 22,841.62 | -453.13 | 229.55B |
| HSCEI1 | 7,690.34 | -145.93 | 94.38B |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-19 16:19:15 Morgan Stanley issued a research report stating that CSPC PHARMA (01093.HK)'s finished drug sales in the third quarter were slightly above expectations, while multiple pipeline catalysts in the future reinforced the bank's investment thesis. The bank maintained its Overweight rating and HKD12 TP on CSPC PHARMA (01093.HK). Morgan Stanley noted that the company targets continued positive growth in finished drug sales by 2027. There was no price cut for NBP under the national volume-based procurement program, while Mingfule recorded an about 9% price reduction in the National Reimbursement Drug List. In total, the company has more than 10 innovative drugs. Third-quarter finished drug sales rose 10% YoY and 2.5% QoQ. Among them, central nervous system (CNS) drugs increased 32% YoY, oncology drugs fell 23%, anti-infective drugs rose 2%, cardiovascular drugs declined 15%, respiratory drugs dropped 15%, digestive drugs increased 41%, and other drugs fell 2%. Third-quarter business development income reached RMB373 million, while business development income for the first nine months of 2026 amounted to RMB6.3 billion, including part of the upfront payments and milestone payments from AstraZeneca's long-acting peptide platform and Nectin-4 ADC. Third-quarter gross margin rose 1 ppts YoY to 67%, while the selling and administrative expense ratio for finished drug sales fell 6 ppts. The R&D ratio remained broadly stable at 31%, and adjusted net profit for the third quarter increased 39% YoY. The bank said the next catalysts include Phase III readout data for EGFR ADC in second-line EGFR-mutated non-small cell lung cancer to be announced at ESMO Asia in early December, as well as early durability data and potential globalization updates for PD-1/IL-15 in 2027. (da/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |